Vimarsana
Biggest News Aggregation in the World

Stat Facts News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Stat Facts. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Stat Facts Today - Breaking & Trending Today

FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer - Vimarsana News

FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer

Published: April 29, 2024

TIVDAK is the first antibody-drug conjugate to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer Conversion to full approval from...

Source: marketscreener.com
Related Topics:
Miami BeachNew JerseyUnited StatesChris BoshoffBrian SlomovitzTamika FelderCompany AnnouncementEuropean Society Of Medical OncologyAmerican Cancer SocietyEuropean Network Of Gynaecological Oncological Trial GroupsAmerican Society Of Clinical OncologyPfizer IncNational Cancer InstituteExchange CommissionGynecologic Oncology GroupCervivor IncDrug AdministrationBiologics License ApplicationChief Oncology OfficerExecutive Vice PresidentEuropean SocietyMedical OncologyChief Executive OfficerOcular ToxicityImportant Safety
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial - Vimarsana News

ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial

Published: April 29, 2024

Daiichi Sankyo and AstraZeneca’s ENHERTU also demonstrated a clinically meaningful progression-free survival improvement in patients with HER2 ultralow expression Plans for global regulatory...

Source: marketscreener.com
Related Topics:
Israel GeneralDaiichi SankyoNational Cancer InstituteDaiichi Sankyo IncLow Metastatic Breast CancerSolid TumorsPositive Locally AdvancedMetastatic Gastric CancerAdverse ReactionsPositive Metastatic Breast CancerMutant UnresectableMetastatic Solid TumorsReproductive PotentialHepatic ImpairmentPrescribing InformationCancer ResStat FactsFemale Breast CancerAccessed AprilPathol Transl
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer - Vimarsana News

TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

Published: April 29, 2024

Company Announcement Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapyTIVDAK is the first antibody-drug conjugate in this patient...

Source: marketscreener.com
Related Topics:
Miami BeachNew JerseyUnited StatesChris BoshoffBrian SlomovitzTamika FelderMarisol PeronAndrew CarlsenExchange CommissionNational Cancer InstitutePfizer IncGlobal Communications Corporate AffairsAmerican Society Of Clinical OncologyDrug AdministrationCervivor IncGynecologic Oncology GroupCompany AnnouncementEuropean Network Of Gynaecological Oncological Trial GroupsAmerican Cancer SocietyEuropean Society Of Medical OncologyBiologics License ApplicationPresidential SymposiumEuropean SocietyMedical OncologyGynecologic Oncology
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer - Vimarsana News

TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

Published: April 29, 2024

Company Announcement Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapy TIVDAK is the first antibody-drug conjugate in this...

Source: marketscreener.com
Related Topics:
Miami BeachNew JerseyUnited StatesChris BoshoffBrian SlomovitzTamika FelderExchange CommissionAmerican Society Of Clinical OncologyPfizer IncNational Cancer InstituteDrug AdministrationGynecologic Oncology GroupCervivor IncCompany AnnouncementAmerican Cancer SocietyEuropean Network Of Gynaecological Oncological Trial GroupsEuropean Society Of Medical OncologyBiologics License ApplicationPresidential SymposiumEuropean SocietyMedical OncologyGynecologic OncologyCancer Research CommitteeMount Sinai Medical CenterChief Executive Officer
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer - Vimarsana News

TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

Published: April 29, 2024

COPENHAGEN, Denmark--(BUSINESS WIRE)--Apr 29, 2024--

Source: eagletribune.com
Related Topics:
Miami BeachNew JerseyUnited StatesBrian SlomovitzMarisol PeronPfizerand GenmabwillTamika FelderChris BoshoffAndrew CarlsenEuropean Society Of Medical OncologyAmerican Cancer SocietyPfizer IncGynecologic Oncology GroupCervivor IncGlobal Communications Corporate AffairsExchange CommissionCompany AnnouncementAmerican Society Of Clinical OncologyNational Cancer InstituteEuropean Network Of Gynaecological Oncological Trial GroupsDrug AdministrationBiologics License ApplicationPresidential SymposiumEuropean SocietyMedical Oncology